Related Experiment Video
Updated: Apr 12, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.4K
Janus kinase inhibitors: jackpot or potluck?
Keechilat Pavithran1, Shripad Brahmanand Pande1
1Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Kochi, India.
Oncology Reviews
|May 21, 2015
Summary
Janus kinase (JAK) inhibitors, like ruxolitinib, have transformed myeloproliferative neoplasm (MPN) management. While offering benefits, potential disadvantages like toxicity and resistance require careful consideration for future JAK inhibitor development.
Area of Science:
- Biomedical research
- Translational medicine
- Oncology
Background:
- Discovery of Janus kinase-2 (JAK2) mutation in polycythemia vera in 2005.
- Rapid development of JAK inhibitors spurred by this finding.
- Ruxolitinib as the first small-molecule JAK inhibitor in clinical trials.
Purpose of the Study:
- To review the impact of JAK inhibitors on myeloproliferative neoplasms (MPNs).
- To discuss the paradigm shift in MPN management with ruxolitinib.
- To explore potential benefits and drawbacks of JAK inhibitors.
Main Methods:
- Review of translational research and clinical trial data.
- Analysis of ruxolitinib's approval and application in myelofibrosis.
- Discussion of current evidence and future directions for JAK inhibitors.
Main Results:
- Ruxolitinib approval in 2011 marked a significant change in managing intermediate-2 and high-risk myelofibrosis.
- JAK inhibitors show potential for improved disease control and survival in various MPN risk categories.
- Potential disadvantages include toxicity, resistance, and withdrawal phenomena.
Conclusions:
- JAK inhibitors represent a major advancement in MPN treatment.
- Further research is needed to optimize potency and address limitations.
- JAK inhibitors are likely to have broader applications beyond MPNs.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
14.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.1K
01:22PI3K/mTOR/AKT Signaling Pathway
6.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.4K
01:25cAMP-dependent Protein Kinase Pathways
9.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.3K
02:54Protein Kinases and Phosphatases
4.7K
4.7K
02:54Protein Kinases and Phosphatases
15.7K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.7K
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K